$2.2b HPV vax sales
March 21, 2014
The global prophylactic human
papillomavirus (HPV) vaccine
market value has been forecast
to increase by 2.6% from 2012 to
2022, from US$1.7b and US$2.2b.
This is according to a report
from research and consulting
firm GlobalData, which was
formed using data sourced from
proprietary databases, primary and
secondary research and in-house
analysis.
HPV vaccine sales in Australia
and Canada were expected to
grow at the largest compound
annual growth rate of more
than 9%, driven by the launch of
Merck’s V503 vaccine, and the
inclusion of males in HPV vaccine
recommendations, the report said.
Obstacles to the market’s growth
included low coverage rates and
vaccine safety fears, it said.
To read the report, CLICK HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 21 Mar 14To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 21 Mar 14
